Progering

Product Overview

Alternative Name: Progesterone Vaginal Ring (PVR)

Development Status: Limited Market Approval

Target: Female

Mode: Hormonal

Delivery Type: Vaginal Ring

Duration Type: Long-acting

Description: A progesterone only 3-month vaginal ring, marketed specifically for breastfeeding women. Progesterone prevents resumption of ovulation and prolongs lactational amenorrhea. Given its short half-life orally, it is destroyed when ingested in mother's milk and there is no impact on the infant.

Updated date: May 30, 2018

Vertical Tabs

Status

Project Phase: Post-development

Project Stage: Regulatory

Began discovery in: mid-1990'

Status Details:
  • Progering (developed by Population Council, CONRAD, UNFPA and Silesia) has been approved for use in Bolivia, Chile, Ecuador, Guatemala, Dominican Republic, El Salvador, Panama, and Peru.
  • Additional phase III study ongoing in India for submission to Government of India for approval. Additional acceptability studies ongoing in sub-Saharan Africa in preparation for introduction.
  • It is under evaluation at WHO for the Essential Medicine list and prequalification program at manufacturing site.

Download Product Report